Immune checkpoint inhibitors and corneal transplant rejection: a call for awareness.

Harpal Singh Sandhu*,1, Houman D Hemmati2 & Reza Dana3 1Department of Ophthalmology & Visual Sciences, University of Louisville, Louisville, KY 40202, USA 2Department of Ophthalmology, Roski Eye Institute, University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA 3Department of Ophthalmology, Massachusetts Eye & Ear Infirmary, Harvard Medical School, Boston, MA 02114, USA *Author for correspondence: Tel.: +1 502 588 0550; Fax: +1 502 588 0553; harpal.sandhu@gmail.com

[1]  V. Kruse,et al.  Bilateral Corneal Graft Rejection Associated With Pembrolizumab Treatment. , 2020, Cornea.

[2]  A. Shinagare,et al.  The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature. , 2020, The oncologist.

[3]  S. Markovic,et al.  Systematic Review of the Safety of Immune Checkpoint Inhibitors Among Kidney Transplant Patients , 2019, Kidney international reports.

[4]  M. Suarez‐Almazor,et al.  Use of checkpoint inhibitors (CPI) in allogeneic stem cell transplant recipients: An institutional experience and a systemic review of the literature , 2019, Annals of Oncology.

[5]  M. Suarez‐Almazor,et al.  Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature , 2019, Journal of Immunotherapy for Cancer.

[6]  H. Van Vlierberghe,et al.  Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go? , 2019, Current opinion in oncology.

[7]  P. Gohier,et al.  Corneal graft rejection in a patient treated with nivolumab for primary lung cancer. , 2016, Lung cancer.

[8]  R. Chuck,et al.  Keratoplasty in the United States: A 10-Year Review from 2005 through 2014. , 2015, Ophthalmology.

[9]  D. Schmid,et al.  Renal tubular PD-L1 (CD274) suppresses alloreactive human T-cell responses. , 2010, Kidney international.

[10]  M. Mochizuki,et al.  Suppression of bystander T helper 1 cells by iris pigment epithelium-inducing regulatory T cells via negative costimulatory signals. , 2010, Investigative ophthalmology & visual science.

[11]  G. Freeman,et al.  The Function of Donor versus Recipient Programmed Death-Ligand 1 in Corneal Allograft Survival1 , 2007, The Journal of Immunology.

[12]  K. Okumura,et al.  B7-H1-Induced Apoptosis as a Mechanism of Immune Privilege of Corneal Allografts1 , 2006, The Journal of Immunology.

[13]  D. Larkin,et al.  Differential effects of costimulatory pathway modulation on corneal allograft survival. , 2006, Investigative ophthalmology & visual science.

[14]  J. Streilein.  New thoughts on the immunology of corneal transplantation , 2003, Eye.

[15]  M. Mochizuki,et al.  Human corneal endothelial cells expressing programmed death-ligand 1 (PD-L1) suppress PD-1+ T helper 1 cells by a contact-dependent mechanism. , 2009, Investigative ophthalmology & visual science.